AR075345A1 - Tratamiento con glucocorticoides de liberacion retardada de artritis reumatoidea que mejora signos y sintomas, muestra respuesta clinica total o completa y previene el dano a las articulaciones - Google Patents

Tratamiento con glucocorticoides de liberacion retardada de artritis reumatoidea que mejora signos y sintomas, muestra respuesta clinica total o completa y previene el dano a las articulaciones

Info

Publication number
AR075345A1
AR075345A1 ARP100100242A ARP100100242A AR075345A1 AR 075345 A1 AR075345 A1 AR 075345A1 AR P100100242 A ARP100100242 A AR P100100242A AR P100100242 A ARP100100242 A AR P100100242A AR 075345 A1 AR075345 A1 AR 075345A1
Authority
AR
Argentina
Prior art keywords
glucocorticoid
inhibitor
dose
symptoms
rheumatoid arthritis
Prior art date
Application number
ARP100100242A
Other languages
English (en)
Inventor
Achim Schaeffler
Original Assignee
Nitec Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitec Pharma Ag filed Critical Nitec Pharma Ag
Publication of AR075345A1 publication Critical patent/AR075345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente se refiere al tratamiento de un paciente que padece de artritis reumatoidea que muestra una reduccion en los signos y síntomas, una respuesta clínica total o completa (remision) o incluso prevencion de los danos estructurales a las articulaciones mediante la administracion de una forma de dosis de liberacion retardada de un glucocorticoide a un sujeto que lo necesita. Reivindicacion 6: El método de acuerdo con la reivindicacion 1, 2, 3 o 4, caracterizado porque la dosis de glucocorticoide es igual o inferior a alrededor de 10 mg/día de prednisona o una cantidad equivalente de otro glucocorticoide para el inicio y mantenimiento de la terapia. Reivindicacion 13: El método de acuerdo con la reivindicacion 1, 2, 3 o 4, caracterizado porque dicho paciente no fue previamente tratado con un glucocorticoide de liberacion inmediata oral, una NSAID, una DMARD, un inhibidor de TNFalfa, un inhibidor de IL-1, un inhibidor de lL-6, un agente analgésica, o combinaciones de los mismos. Reivindicacion 14: El método de acuerdo con la reivindicacion 1 2, 3 o 4, caracterizado porque dicho paciente se sometio previamente a tratamiento con una NSAID, una DMARD, un inhibidor de TNFalfa, un inhibidor de lL-1, un inhibidor de IL-6, un agente analgésico, o combinaciones de los mismos. Reivindicacion 19: El método de acuerdo con la reivindicacion 1, 2, 3 o 4, caracterizado porque dicha forma de dosis de liberacion retardada es más efectiva en la misma dosis de glucocorticoide en comparacion con la administracion de dicho glucocorticoide contenido en una forma de dosis de Iiberacion inmediata. Reivindicacion 27: El método de acuerdo con la reivindicacion 1. 2, 3 o 4, caracterizado porque la forma de dosis de liberacion retardada es una tableta o una cápsula.
ARP100100242A 2009-01-30 2010-01-29 Tratamiento con glucocorticoides de liberacion retardada de artritis reumatoidea que mejora signos y sintomas, muestra respuesta clinica total o completa y previene el dano a las articulaciones AR075345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14843509P 2009-01-30 2009-01-30

Publications (1)

Publication Number Publication Date
AR075345A1 true AR075345A1 (es) 2011-03-23

Family

ID=42397916

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100242A AR075345A1 (es) 2009-01-30 2010-01-29 Tratamiento con glucocorticoides de liberacion retardada de artritis reumatoidea que mejora signos y sintomas, muestra respuesta clinica total o completa y previene el dano a las articulaciones

Country Status (4)

Country Link
US (3) US20100196427A1 (es)
AR (1) AR075345A1 (es)
NZ (1) NZ582836A (es)
TW (1) TW201034704A (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96457C2 (ru) 2006-08-03 2011-11-10 Нитек Фарма Аг Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением
CA2749646A1 (en) * 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
WO2013030726A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Programmed drug delivery
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) * 1958-08-04 1962-08-07 Wander Company Medicinal tablet
US3125491A (en) * 1962-04-06 1964-03-17 Chew able hematinic vitamin tablet
US5519057A (en) * 1986-11-14 1996-05-21 Johnson & Johnson--Merck Pharmaceuticals Co. Ibuprofen-containing medicament
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US4966770A (en) * 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5702723A (en) * 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
US5567969A (en) * 1995-04-20 1996-10-22 Hall; John H. Compound modulated integrated transistor structure with reduced bipolar switch back effect
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
ATE277739T1 (de) * 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US7201923B1 (en) * 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6887493B2 (en) * 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US6589562B1 (en) * 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6565873B1 (en) * 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
DE60237363D1 (de) * 2001-03-15 2010-09-30 Soligenix Inc Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
US20030021841A1 (en) * 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
AU2002334939A1 (en) * 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
US20030203030A1 (en) * 2002-01-18 2003-10-30 Control Delivery Systems, Inc. Polymeric gel delivery system for pharmaceuticals
AU2003208761A1 (en) * 2002-02-21 2003-09-09 Amarin Development Ab A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
EP1585502B9 (en) * 2002-11-12 2012-05-09 Elan Pharma International Limited Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
ATE445393T1 (de) * 2003-04-24 2009-10-15 Jagotec Ag Tablette mit gefärbtem kern
BRPI0409652A (pt) * 2003-04-24 2006-04-25 Jagotec Ag tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete
US20060177507A1 (en) * 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
DE102004043863A1 (de) * 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
WO2007002597A2 (en) * 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
WO2007036952A2 (en) * 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
US20080248107A1 (en) * 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
UA96457C2 (ru) * 2006-08-03 2011-11-10 Нитек Фарма Аг Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением
CA2749646A1 (en) * 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma

Also Published As

Publication number Publication date
US20100196427A1 (en) 2010-08-05
TW201034704A (en) 2010-10-01
US20140349980A1 (en) 2014-11-27
US20130190279A1 (en) 2013-07-25
NZ582836A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
GEP20156281B (en) Orally administered corticosteroid compositions
JP2015038135A5 (es)
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
RS53491B1 (en) Compositions for the treatment of centrally mediated nausea and vomiting
DK2437749T3 (da) Kombineret fremgangsmåde til behandling af kræft eller en præcancerøs tilstand
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
BR112013000190A2 (pt) formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
RU2014142066A (ru) Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
MX2015009055A (es) Forma de dosificacion oral de liberacion sostenida gastro retentiva de un secuestrante de acido biliar.
SG10201901677YA (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
AR075345A1 (es) Tratamiento con glucocorticoides de liberacion retardada de artritis reumatoidea que mejora signos y sintomas, muestra respuesta clinica total o completa y previene el dano a las articulaciones
JP2012502909A5 (es)
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
Khan et al. Pharmacological management of acute endodontic pain
UY31363A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
DK1830857T3 (da) Beclomethasondipropionat og prednison til reducering af dødelighed associeret med Graft-Versus-Host sygdom
RU2013126798A (ru) Комбинированная терапия дексаметазоном
MX2014003093A (es) Combinacion de pterostilbeno y estatina para el tratamiento de enfermedad metabolica, enfermedad cardiovascular e inflamacion.
Jamshidi et al. Attitude of dentists towards the administration of analgesics for management of post-endodontic pain in Hamadan
MD20160131A2 (ro) Compus de tiacumicină şi regim de tratament asociat

Legal Events

Date Code Title Description
FB Suspension of granting procedure